COLLECTIONS
WORKFLOWS
Recent Finacing
Recent Raise
AIRNA develops RNA‑editing therapeutics using its RESTORE+ platform that programs oligonucleotides to recruit endogenous ADAR, advancing a lead AIR‑001 candidate for alpha‑1 antitrypsin deficiency and a multi‑program pipeline.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
